Roche, NICE in Avastin data standoff

It's another blow for Roche's Avastin the U.K. The National Institute for Clinical Health and Excellence shot down the high-tech cancer med as a first-line treatment for lung and breast cancer, meaning the National Health Service won't pay for it. That's the second rejection at NICE for Avastin, which was also denied for colon cancer use.

The negative verdict came after NICE asked Roche for more data on the drug's clinical and cost-effectiveness--and Roche refused, figuring the data would just show that Avastin was too expensive to meet the agency's requirements. With the announcement came the expected rhetorical clash. "Other healthcare systems seem to think it's fairly priced," a Roche spokesman sniffed. NICE's chairman sniped, "Roche would rather not supply the drug in the U.K. than risk a negative opinion."

Avastin's thumbs-down comes at a time when expensive cancer meds are under increasing scrutiny in the U.K. And because NICE tends to be influential in the drug-reimbursement world, that scrutiny could follow cancer treatments to other countries, too.

- check out NICE's statement
- get the news from Interactive Investor
- see the Financial Times story

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.